Monoclonal antibodies in oncological malignancies: Current status and future directions

Terry Ann Harding, Christine A. Gallati, Michael Horlacher, Amy Becker, Shaker A. Mousa

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Recently, extensive research has been done in the area of bio-oncology. Bio-oncology focuses on four targets in particular: angiogenesis, signal transduction, B-cell biology and apoptosis. Monoclonal antibodies (mAbs) are a novel technology that can offer a world of opportunity by interfering with these pathways. In the past decade, a number of antibody-based products have emerged for the treatment of patients with different types of cancer. To date, nine therapeutic mAbs have been approved by the FDA for the treatment of oncologic diseases. This review explores these mAbs and analyzes their mechanism of action, as well as side effects specific to each. It also focuses on the unique features and limitations of mAbs as a mode of therapy and looks at some of the possible future endeavors for this novel therapeutic class.

Original languageEnglish (US)
Pages (from-to)361-369
Number of pages9
JournalDrugs of the Future
Volume33
Issue number4
DOIs
StatePublished - Apr 1 2008

Fingerprint

Monoclonal Antibodies
Neoplasms
Therapeutics
Cell Biology
Signal Transduction
B-Lymphocytes
Direction compound
Apoptosis
Technology
Antibodies
Research

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Harding, T. A., Gallati, C. A., Horlacher, M., Becker, A., & Mousa, S. A. (2008). Monoclonal antibodies in oncological malignancies: Current status and future directions. Drugs of the Future, 33(4), 361-369. https://doi.org/10.1358/dof.2008.033.04.1186448
Harding, Terry Ann ; Gallati, Christine A. ; Horlacher, Michael ; Becker, Amy ; Mousa, Shaker A. / Monoclonal antibodies in oncological malignancies : Current status and future directions. In: Drugs of the Future. 2008 ; Vol. 33, No. 4. pp. 361-369.
@article{23d88d41c6724a49b2609d7882a91a69,
title = "Monoclonal antibodies in oncological malignancies: Current status and future directions",
abstract = "Recently, extensive research has been done in the area of bio-oncology. Bio-oncology focuses on four targets in particular: angiogenesis, signal transduction, B-cell biology and apoptosis. Monoclonal antibodies (mAbs) are a novel technology that can offer a world of opportunity by interfering with these pathways. In the past decade, a number of antibody-based products have emerged for the treatment of patients with different types of cancer. To date, nine therapeutic mAbs have been approved by the FDA for the treatment of oncologic diseases. This review explores these mAbs and analyzes their mechanism of action, as well as side effects specific to each. It also focuses on the unique features and limitations of mAbs as a mode of therapy and looks at some of the possible future endeavors for this novel therapeutic class.",
author = "Harding, {Terry Ann} and Gallati, {Christine A.} and Michael Horlacher and Amy Becker and Mousa, {Shaker A.}",
year = "2008",
month = "4",
day = "1",
doi = "10.1358/dof.2008.033.04.1186448",
language = "English (US)",
volume = "33",
pages = "361--369",
journal = "Drugs of the Future",
issn = "0377-8282",
publisher = "Prous Science",
number = "4",

}

Harding, TA, Gallati, CA, Horlacher, M, Becker, A & Mousa, SA 2008, 'Monoclonal antibodies in oncological malignancies: Current status and future directions', Drugs of the Future, vol. 33, no. 4, pp. 361-369. https://doi.org/10.1358/dof.2008.033.04.1186448

Monoclonal antibodies in oncological malignancies : Current status and future directions. / Harding, Terry Ann; Gallati, Christine A.; Horlacher, Michael; Becker, Amy; Mousa, Shaker A.

In: Drugs of the Future, Vol. 33, No. 4, 01.04.2008, p. 361-369.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Monoclonal antibodies in oncological malignancies

T2 - Current status and future directions

AU - Harding, Terry Ann

AU - Gallati, Christine A.

AU - Horlacher, Michael

AU - Becker, Amy

AU - Mousa, Shaker A.

PY - 2008/4/1

Y1 - 2008/4/1

N2 - Recently, extensive research has been done in the area of bio-oncology. Bio-oncology focuses on four targets in particular: angiogenesis, signal transduction, B-cell biology and apoptosis. Monoclonal antibodies (mAbs) are a novel technology that can offer a world of opportunity by interfering with these pathways. In the past decade, a number of antibody-based products have emerged for the treatment of patients with different types of cancer. To date, nine therapeutic mAbs have been approved by the FDA for the treatment of oncologic diseases. This review explores these mAbs and analyzes their mechanism of action, as well as side effects specific to each. It also focuses on the unique features and limitations of mAbs as a mode of therapy and looks at some of the possible future endeavors for this novel therapeutic class.

AB - Recently, extensive research has been done in the area of bio-oncology. Bio-oncology focuses on four targets in particular: angiogenesis, signal transduction, B-cell biology and apoptosis. Monoclonal antibodies (mAbs) are a novel technology that can offer a world of opportunity by interfering with these pathways. In the past decade, a number of antibody-based products have emerged for the treatment of patients with different types of cancer. To date, nine therapeutic mAbs have been approved by the FDA for the treatment of oncologic diseases. This review explores these mAbs and analyzes their mechanism of action, as well as side effects specific to each. It also focuses on the unique features and limitations of mAbs as a mode of therapy and looks at some of the possible future endeavors for this novel therapeutic class.

UR - http://www.scopus.com/inward/record.url?scp=45949093591&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45949093591&partnerID=8YFLogxK

U2 - 10.1358/dof.2008.033.04.1186448

DO - 10.1358/dof.2008.033.04.1186448

M3 - Review article

AN - SCOPUS:45949093591

VL - 33

SP - 361

EP - 369

JO - Drugs of the Future

JF - Drugs of the Future

SN - 0377-8282

IS - 4

ER -